Intravenous thrombolytic therapy in acute stroke

Area of Science:

• Neurology
• Cardiology
• Pharmacology

Background:

• Thrombolytic therapy aims to dissolve blood clots, improving outcomes in hyperacute stroke.
• Intravenous thrombolysis has been evaluated in multiple large clinical trials for acute ischemic stroke treatment.

Purpose of the Study:

• To review the evidence supporting thrombolytic therapy for acute stroke.
• To summarize the results of recent clinical trials and discuss methodological factors influencing outcomes.

Main Methods:

• Review of experimental data and results from five major clinical trials on intravenous thrombolysis for stroke.
• Analysis of factors such as drug type, dosage, timing, and patient selection criteria.

Main Results:

• Four of five trials showed negative or equivocal results, potentially due to methodological issues.
• The NINDS rt-PA trial demonstrated significant benefit when recombinant tissue plasminogen activator (rt-PA) was administered within 3 hours with strict criteria.
• rt-PA is FDA-approved for acute stroke, but carries an elevated risk of bleeding.

Conclusions:

• Thrombolytic therapy, specifically rt-PA, can be beneficial for acute stroke within a narrow time window.
• Achieving a favorable risk/benefit ratio requires careful patient selection, exclusion of contraindications, and expert interpretation of brain CT scans.
• Guidelines for rt-PA use and future strategies are essential for optimizing treatment.